Ocugen Inc (NAS:OCGN)
$ 1.27 -0.11 (-7.97%) Market Cap: 326.84 Mil Enterprise Value: 335.61 Mil PE Ratio: 0 PB Ratio: 10.58 GF Score: 34/100

Ocugen Inc at ROTH Conference Transcript

Mar 13, 2023 / 04:00PM GMT
Release Date Price: $0.9095 (-1.60%)
Jonathan Aschoff
ROTH Capital Partners, LLC - Analyst

I'm Jonathan Aschoff, senior biotechnology analyst at ROTH MKM; and with us now is Shankar Musunuri, the CEO of Ocugen. And hello, Shankar. Welcome.

Shankar Musunuri
Ocugen, Inc. - Chairman of the Board, CEO, & Co-Founder

Thank you. Thank you, Jonathan. Thank you for having me.

Questions & Answers

Jonathan Aschoff
ROTH Capital Partners, LLC - Analyst

It's great to have you. So your company has had a diversified portfolio, gene therapy, cell therapy, biologics, vaccine. You're running the whole gamut here. How did that happen, and what are some unifying characteristics you can tell us that have led to that?

Shankar Musunuri
Ocugen, Inc. - Chairman of the Board, CEO, & Co-Founder

Yeah. You have, starting with the shared science, you take gene therapies and vaccines with their novel vectors, there are a lot of commonalities. And there is also manufacturing change platform with a lot of similarities.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot